Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

Septerna, Inc. SEPN

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$46.0M
▲ 4174.5% YoY
$-48.9M
$109.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 46.0M
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 46.0 · Net income -48.9
20M40M-30M-60M
202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−106 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -148.6%
-10000%-20000%-30000%
202320242025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.

Each USD of equity lost 12 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 109.7
50.0M100.0M-25.0M-50.0M
202320242025

Total assetsUSD 596.2M
EquityUSD 381.9M
CashUSD 120.7M
Current ratio4.73×

Equity funds 64% of total assets.

The 3-year record

3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SEPN, 3-year financial record
Metric 202520242023
Revenue $B0.00.00.0
Operating income $B−0.1−0.1−0.0
EBITDA $B−0.1−0.1−0.0
Income tax $B0.0−0.00.0
Net income $B−0.0−0.10.0
Free cash flow $B0.1−0.1−0.0
EPS, diluted $−1.10−7.260.29
Dividend / sh $◌◌◌
Payout % — not applicable: no dividend———
ROE %−12.2——
Shares out B0.040.040.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 12 reconciliationsAUDITED

Reconciled in 3 of the 3 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 16 checks were skipped: EPS is not tagged before 2023.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2023

Share this section

Download image